Rheos Capital Works’s Edwards Lifesciences EW Stock Holding History

Rheos Capital Works’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-258,165	Closed	-$17.9M	–	103
2023 Q3	$17.9M	Buy	258,165 +100,000	+63%	+$8.04M	1.08%	33
2023 Q2	$14.9M	Hold	158,165	–	–	0.8%	41
2023 Q1	$13.1M	Sell	158,165 -22,000	-12%	-$1.73M	0.73%	52
2022 Q4	$13.4M	Hold	180,165	–	–	0.81%	44
2022 Q3	$14.9M	Hold	180,165	–	–	1%	34
2022 Q2	$17.1M	Hold	180,165	–	–	1.29%	19
2022 Q1	$21.2M	Hold	180,165	–	–	1.02%	33
2021 Q4	$23.3M	Hold	180,165	–	–	1.02%	30
2021 Q3	$20.4M	Hold	180,165	–	–	1.05%	31
2021 Q2	$18.7M	Buy	180,165 +25,000	+16%	+$2.36M	0.94%	35
2021 Q1	$13M	Buy	155,165 +20,000	+15%	+$1.69M	0.86%	42
2020 Q4	$12.3M	Hold	135,165	–	–	0.9%	35
2020 Q3	$10.8M	Hold	135,165	–	–	0.88%	25
2020 Q2	$9.34M	Buy	135,165 +17,400	+15%	+$1.24M	0.65%	29
2020 Q1	$7.4M	Buy	+117,765	New	+$8.49M	0.79%	24

Other funds holding EW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Rheos Capital Works's EW Position: Q4 2023 in Review

Rheos Capital Works sold out of Edwards Lifesciences (EW) in Q4 2023, closing a stake of 258,165 shares — an estimated $17.9M sold.

Rheos Capital Works first reported a position in EW in Q1 2020 and held it in 15 quarters. The position peaked at $23.3M in Q4 2021. 1,245 funds tracked by Wall St. Rank hold EW as of Q4 2023.

Rheos Capital Works reported no remaining Edwards Lifesciences position as of Q4 2023 after selling out during the quarter.
Rheos Capital Works sold 258,165 Edwards Lifesciences shares in Q4 2023, an estimated $17.9M.
Rheos Capital Works first reported a position in Edwards Lifesciences in Q1 2020 and held it in 15 quarters.
Rheos Capital Works's Edwards Lifesciences position peaked at $23.3M in Q4 2021.
1,245 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2023.

Based on Rheos Capital Works's 13F filing for Q4 2023, filed 16 Jan 2024.